淋巴组织肿瘤患者合并细菌性血流感染的临床与细菌学分析
该研究回顾性分析2010年9月至2014年12月淋巴组织肿瘤合并细菌性血流感染患者的临床资料与药敏结果,共107例患者发生134例次血流感染。分离144株病原菌,革兰阴性菌占75.0%,对碳青霉烯类敏感率98.00%;革兰阳性菌对糖肽类及利奈唑胺敏感率100.0%。结论为化疗后最常见,革兰阴性菌多见,碳青霉烯类敏感率最高且治疗调整率低。
要点
- 淋巴肿瘤患者细菌性血流感染多发生于急性淋巴细胞白血病方案化疗后。
- 病原菌以革兰阴性菌为主(108/144株,75.0%)。
- 革兰阴性菌对碳青霉烯类敏感率98.00%,治疗调整率3.0%;革兰阳性菌对糖肽类及利奈唑胺敏感率100.0%。
核心结论
- 淋巴肿瘤患者发生细菌性血流感染以急性淋巴细胞白血病方案化疗后最常见,致病菌以革兰阴性菌多见。
- 革兰阴性菌对碳青霉烯类抗生素敏感性最高且治疗调整率明显更低;革兰阳性菌对糖肽类抗菌药物和利奈唑胺敏感性高,可依据药敏结果用于革兰阳性球菌脓毒症患者。
研究设计与样本
- 回顾性分析2010年9月至2014年12月发生细菌性血流感染的淋巴肿瘤患者的临床资料和细菌药敏试验结果。
- 共107例患者发生134例次血流感染,其中男84例、女50例,中位年龄31(12-71)岁。
主要发现
- 112例次为粒细胞缺乏,其中106例次为严重粒细胞缺乏(ANC<0.1×10(9)/L)。
- 原发病治疗:造血干细胞移植27例次,化疗100例次(VD(I)CP±L方案33例次、Hyper-CVAD/MA或MA方案41例次、其他化疗方案26例次),未化疗7例次。
- 共分离病原菌144株,革兰阴性菌108株(75.0%),革兰阳性菌36株(25.0%)。
- 革兰阴性菌对碳青霉烯类敏感率98.00%、治疗调整率3.0%;对非碳青霉烯类抗菌药物敏感率60.30%、治疗调整率90.5%。
- 革兰阳性菌对碳青霉烯类敏感率49.3%,对万古霉素或替考拉宁、利奈唑胺敏感率100.0%;80.1%患者初始经验性用药即为敏感药物。
关键数值与推荐
- 革兰阴性菌对碳青霉烯类抗生素敏感率为98.00%,治疗调整率为3.0%。
- 革兰阴性菌对非碳青霉烯类抗菌药物敏感率为60.30%,治疗调整率为90.5%。
- 革兰阳性菌对碳青霉烯类抗生素敏感率为49.3%,对万古霉素或替考拉宁、利奈唑胺敏感率为100.0%。
- 80.1%的患者初始经验性用药与血培养药敏结果比照即为敏感药物。
临床怎么用
- 作者认为革兰阳性菌对糖肽类抗菌药物、利奈唑胺敏感性高,可依据药敏结果用于革兰阳性球菌脓毒症患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the clinical status of lymphoid tissue neoplasms patients with bacteria bloodstream infections, bacteriology and drug susceptibility results, and provide the basis for rational clinical anti-infection option. Methods: A retrospectively analysis of clinical data and bacterial susceptibility test results of patients with bacteria bloodstream infections from September 2010 to December 2014 was conducted. Results: A total of 134 cases including 107 patients with bloodstream infections were enrolled. 84 cases were male, 50 cases were female, the median age was 31 (12-71) years old. 112 cases were agranulocytosis, and 106 cases were severe agranulocytosis (ANC<0.1×10(9)/L) . 27 cases underwent hematopoietic stem cell transplantation, 100 cases received chemotherapy[33 cases with VD (I) CP±L (vincristine+daunorubicin/idarubicin + cyclophosphamide + prednison±asparaginasum) induction chemotherapy, 41 cases with intensive chemotherapy of Hyper-CVAD/MA or MA (mitoxantrone+cytarabine) , 26 cases with other chemotherapy regimens], and 7 cases were infected without chemotherapy. 10 patients discharged from hospital owing to treatment abandoning, 120 cases were cured through anti-infective therapy, 2 patients died of bacteria bloodstream infections, 1 patient died of sudden cardiac, and 1 patient died of GVHD after allogenic hematopoietic stem cell transplantation. A total of 144 strains were isolated, including 108 strains (75.0%) of Gram-negative bacteria and 36 strains (25.0%) of Gram-positive cocci. The susceptibility of Gram-negative bacteria to the carbapenems was 98.00%, and the adjustment treatment rate of carbapenems was 3.0%. The susceptibility of Gram-negative bacteria to the other antibiotics was 60.30%, and the adjustment treatment rate was 90.5%. The susceptibility of Grampositive cocci to the carbapenems was 49.3%, and to glycopeptides and linezolid was 100.0%. Comparing all patients'empirical use of antimicrobial agents with the drugs susceptibility results of blood cultures, 80.1% of the patients'initial drug selection was sensitive. Conclusion: The lymphoid neoplasms patients experienced bacteria bloodstream infections most often after receiving the chemotherapy regimens of treating acute lymphoblastic leukemia. The majority type of bacteria was Gram-negative bacteria. Drug susceptibility test showed that susceptibility of Gram-negative bacteria to the carbapenems was the highest, and the treatment adjustment rate was obviously lower. The susceptibility of Gram-positive cocci to glycopeptides and linezolid was high, and which could be applied to the patients with Gram-positive cocci sepsis on basis of susceptibility results in general. 目的: 探讨淋巴肿瘤患者细菌性血流感染的临床特征和细菌学及药敏结果,为抗感染治疗选择提供参考。 方法: 回顾性分析2010年9月至2014年12月发生细菌性血流感染淋巴肿瘤患者的临床资料和细菌药敏试验结果。 结果: 共107例患者发生134例次血流感染,其中粒细胞缺乏112例次,106例次为严重粒细胞缺乏(ANC<0.1×10(9)/L)。原发病治疗方案包括:造血干细胞移植27例次;化疗100例次[33例次采用VD(I)CP±L方案(长春新碱+柔红霉素/去甲氧柔红霉素+环磷酰胺+泼尼松±左旋门冬酰胺酶),41例次采用Hyper-CVAD/MA或MA(米托蒽醌+阿糖胞苷)强化疗方案,26例次采用其他化疗方案];未化疗7例次。10例患者放弃治疗出院,120例次患者感染控制好转,2例患者死于脓毒血症,1例患者心源性猝死,1例患者死于移植物抗宿主病。共分离出病原菌144株,其中革兰阴性菌108株(75.0%),革兰阳性菌36株(25.0%)。革兰阴性菌对碳青霉烯类抗生素敏感率为98.00%,治疗调整率为3.0%;对非碳青霉烯类抗菌药物敏感率为60.30%,治疗调整率为90.5%。革兰阳性菌对碳青霉烯类抗生素敏感率为49.3%,对万古霉素或替考拉宁、利奈唑胺敏感率为100.0%。将所有经验性用药与血培养药敏结果比照,80.1%初始用药即为敏感药物。 结论: 发生血流感染的淋巴肿瘤患者以急性淋巴细胞白血病样方案化疗后最常见。致病细菌以革兰阴性菌多见。药敏试验显示革兰阴性菌对碳青霉烯类抗生素敏感性最高,治疗调整率更低。革兰阳性菌对糖肽类抗菌药物、利奈唑胺敏感性高。.
引用
- Wang TY, Li ZJ, Lin QS, et al. [Clinical and bacteriological analysis of lymphoid tissue neoplasms patients with bacteria bloodstream infections]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 29365397. doi:10.3760/cma.j.issn.0253-2727.2017.12.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。